Current and emerging treatments for the management of myasthenia gravis

References

• GrobDBrunnerNNambaTPagalaMLifetime course of myasthenia gravisMuscle Nerve200837214114918059039
   PubMed Web of Science ®Google Scholar
• PhillipsLH2ndTornerJCEpidemiologic evidence for a changing natural history of myasthenia gravisNeurology1996475123312388909435
   PubMed Web of Science ®Google Scholar
• VincentAPalaceJHilton-JonesDMyasthenia gravisLancet200135792742122212811445126
   PubMed Web of Science ®Google Scholar
• GrobDArsuraELBrunnerNGNambaTThe course of myasthenia gravis and therapies affecting outcomeAnn N Y Acad Sci19875054724993318620
   PubMed Web of Science ®Google Scholar
• SchwarzHMestinon (pyridostigmine bromide) in myasthenia gravisCan Med Assoc J19567529810013343058
   PubMedGoogle Scholar
• SimpsonJFWesterbergMRMageeKRMyasthenia gravis. An analysis of 295 casesActa Neurol Scand.196642Suppl 231275957970
   PubMedGoogle Scholar
• MehndirattaMMPandeySKuntzerTAcetylcholinesterase inhibitor treatment for myasthenia gravisCochrane Database Syst Rev20112CD00698621328290
   PubMed Web of Science ®Google Scholar
• HatanakaYHNonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MGNeurology20056591508150916275854
   PubMed Web of Science ®Google Scholar
• SimonHEMyasthenia gravis: effect of treatment with anterior pituitary extractJAMA19351042320652066
   Google Scholar
• GenkinsGKornfeldPOssermanKENambaTGrobDBrunnerNGThe use of ACTH and corticosteroids in myasthenia gravisAnn N Y Acad Sci19711833693744330763
   PubMed Web of Science ®Google Scholar
• PascuzziRMCoslettHBJohnsTRLong-term corticosteroid treatment of myasthenia gravis: report of 116 patientsAnn Neurol19841532912986721451
   PubMed Web of Science ®Google Scholar
• SghirlanzoniAPeluchettiDMantegazzaRFiacchinoFCornelioFMyasthenia gravis: prolonged treatment with steroidsNeurology19843421701746538004
   PubMed Web of Science ®Google Scholar
• CosiVCitterioALombardiMPiccoloGRomaniAErbettaAEffectiveness of steroid treatment in myasthenia gravis: a retrospective studyActa Neurol Scand199184133391927259
   PubMed Web of Science ®Google Scholar
• EvoliABatocchiAPPalmisaniMTLo MonacoMTonaliPLong- term results of corticosteroid therapy in patients with myasthenia gravisEur Neurol199232137431563453
   PubMed Web of Science ®Google Scholar
• BuBYangMXuJGaoBTPanDJCaiYXA prospective study of effectiveness and safety of long-term prednisone therapy in patients with myasthenia gravisZhonghua Shen Jing Ge Za Zhi2000332831 Chinese
   Google Scholar
• HowardFMJrDuaneDDLambertEHDaubeJRAlternate-day prednisone: preliminary report of a double-blind controlled studyAnn N Y Acad Sci1976274596607183591
   PubMed Web of Science ®Google Scholar
• LindbergCAndersenOLefvertAKTreatment of myasthenia gravis with methylprednisolone pulse: a double blind studyActa Neurol Scand19989763703739669469
   PubMed Web of Science ®Google Scholar
• ZhangJWuHEffectiveness of steroid treatment in juvenile myasthenia gravisChinese Journal of Pediatrics19983610612614
   Google Scholar
• WarmoltsJREngelWKBenefit from alternate-day prednisone in myasthenia gravisN Engl J Med1972286117204331158
   PubMed Web of Science ®Google Scholar
• SkeieGOApostolskiSEvoliAGuidelines for treatment of autoimmune neuromuscular transmission disordersEur J Neurol201017789390220402760
   PubMed Web of Science ®Google Scholar
• SathasivamSSteroids and immunosuppressant drugs in myasthenia gravisNat Clin Pract Neurol20084631732718493241
   PubMedGoogle Scholar
• MatellGBergstromKFrankssonCEffects of some immunosuppressive procedures in myasthenia gravisAnn N Y Acad Sci1976274659676183592
   PubMed Web of Science ®Google Scholar
• MertensHGHertelGReutherPRickerKEffect of immunosuppressive drugs (azathioprine)Ann N Y Acad Sci19813776916996951493
   PubMed Web of Science ®Google Scholar
• WitteASCornblathDRParryGJLisakRPSchatzNJAzathioprine in the treatment of myasthenia gravisAnn Neurol19841566026056742794
   PubMed Web of Science ®Google Scholar
• KuksJBMDjojoatmodjoSOosterhuisHJHGAzathioprine myasthenia gravis: observations in 41 patients and a review of literatureNeuromuscul Disord1991164234311822354
   PubMedGoogle Scholar
• MantegazzaRAntozziCPeluchettiDSghirlanzoniACornelioFAzathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravisJ Neurol198823584494533062134
   PubMed Web of Science ®Google Scholar
• HeckmannJMLeePanEBEastmanRWHigh-dose immunosuppressive therapy in generalized myasthenia gravis – a 2-year follow-up studyS Afr Med J200191976577011680327
   PubMed Web of Science ®Google Scholar
• Myasthenia Gravis Clinical Study GroupA randomised clinical trial comparing prednisolone and azathioprine in myasthenia gravis. Results of a second interim analysisJ Neurol Neurosurg Psychiatry19935611115711638229026
   PubMedGoogle Scholar
• PalaceJNewsom-DavisJLeckyBA randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravisNeurology1998506177817839633727
   PubMed Web of Science ®Google Scholar
• GoulonMElkharratDLokiecFGajdosPResults of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravisTransplant Proc.1988203 Suppl 42112173260050
   PubMed Web of Science ®Google Scholar
• BonifatiDMAngeliniCLong-term cyclosporine treatment in a group of severe myasthenia gravis patientsJ Neurol199724495425479352450
   PubMed Web of Science ®Google Scholar
• LavrnicDVujicARakocevic-StojanovicVCyclosporine in the treatment of myasthenia gravisActa Neurol Scand2005111424725215740576
   PubMed Web of Science ®Google Scholar
• TindallRSARollinsJAPhillipsJTGreenleeRGWellsLBelendiukGPreliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravisN Engl J Med1987316127197243547126
   PubMed Web of Science ®Google Scholar
• TindallRSPhillipsJTRollinsJAWellsLHallKA clinical therapeutic trial of cyclosporine in myasthenia gravisAnn N Y Acad Sci19936815395518357194
   PubMed Web of Science ®Google Scholar
• PerezMCBuotWLMercado-DanguilanCBababaldoZGRenalesLDStable remissions in myasthenia gravisNeurology198131132377192824
   PubMed Web of Science ®Google Scholar
• De FeoLGSchottlenderJMartelliNAMolfinoNAUse of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravisMuscle Nerve2002261313612115946
   PubMed Web of Science ®Google Scholar
• CosLMankodiAKTawilRThorntonCAMycophenolate mofetil (MyM) is safe and well tolerated in myasthenia gravis (MG)Neurology200054Suppl 3A137
   Google Scholar
• CiafaloniEMasseyJMTucker-LipscombBSandersDBMycophenolate mofetil for myasthenia gravis: an open-label pilot studyNeurology2001561979911148243
   PubMed Web of Science ®Google Scholar
• ChaudhryVCornblathDRGriffinJWO’BrienRDrachmanDBMycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseasesNeurology2001561949611148242
   PubMed Web of Science ®Google Scholar
• MeriggioliMNCiafaloniEAl-HaykKAMycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerabilityNeurology200361101438144014638974
   PubMed Web of Science ®Google Scholar
• HehirMKBurnsTMAlpersJConawayMRSawaMSandersDBMycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patientsMuscle Nerve201041559359820405499
   PubMed Web of Science ®Google Scholar
• SandersDBHartIKMantegazzaRAn international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravisNeurology200871640040618434638
   PubMed Web of Science ®Google Scholar
• Muscle Study GroupA trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravisNeurology200871639439918434639
   PubMed Web of Science ®Google Scholar
• SandersDBSiddiqiZALessons from two trials of mycophenolate mofetil in myasthenia gravisAnn N Y Acad Sci2008113224925318567876
   PubMed Web of Science ®Google Scholar
• PhanCSandersDBSiddiqiZAMycophenolate mofetil in myasthenia gravis: the unanswered questionExpert Opin Pharmacother20089142545255118778192
   PubMed Web of Science ®Google Scholar
• ZebardastNPatwaHSNovellaSPGoldsteinJMRituximab in the management of refractory myasthenia gravisMuscle Nerve201041337537819852027
   PubMed Web of Science ®Google Scholar
• LindbergCBokaweraMRituximab for severe myasthenia gravis – experience from five patientsActa Neurol Scand2010122422522820199513
   PubMed Web of Science ®Google Scholar
• MaddisonPMcConvilleJFarrugiaMEThe use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndromeJ Neurol Neurosurg Psychiatry2011In press
   PubMed Web of Science ®Google Scholar
• BlumSGillisDBrownHUse and monitoring of low dose rituximab in myasthenia gravisJ Neurol Neurosurg Psychiatry201182665966321071753
   PubMed Web of Science ®Google Scholar
• KonishiTYoshiyamaYTakamoriMClinical study of FK506 in patients with myasthenia gravisMuscle Nerve200328557057414571458
   PubMed Web of Science ®Google Scholar
• KonishiTYoshiyamaYTakamoriMSaidaTthe Japanese FK506 MG Study GroupLong-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)J Neurol Neurosurg Psychiatry200576344845015716549
   PubMed Web of Science ®Google Scholar
• KawaguchiNYoshiyamaYNemotoYMunakataSFukutakeTHattoriTLow-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravisCurr Med Res Opin20042081269127315324529
   PubMed Web of Science ®Google Scholar
• PonsetiJMAzemJFortJMLong-term results of tacrolimus in cyclosporine- and prednisolone-dependant myasthenia gravisNeurology20056491641164315883336
   PubMed Web of Science ®Google Scholar
• PonsetiJMGamezJAzemJLopez-CanoMVilallongaRArmengolMTacrolimus for myasthenia gravis. A clinical study of 212 patientsAnn N Y Acad Sci2008113225426318096852
   PubMed Web of Science ®Google Scholar
• NagaishiAYukitakeMKurodaYLong-term treatment of steroiddependent myasthenia gravis patients with low-dose tacrolimusIntern Med200847873173618421189
   PubMed Web of Science ®Google Scholar
• MinamiNFukijiNDoiSFive-year follow-up with low-dose tacrolimus in patients with myasthenia gravisJ Neurol Sci20113001–2596221035148
   PubMed Web of Science ®Google Scholar
• ZhaoCBZhangXZhangHClinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravisInt Immunopharmacol201111451952421195813
   PubMed Web of Science ®Google Scholar
• NaganeYUtsugisawaKObaraDKondohRTerayamaYEfficacy of low-dose FK506 in the treatment of myasthenia gravis – a randomized pilot studyEur Neurol200553314615015900097
   PubMed Web of Science ®Google Scholar
• Fateh-MoghadamAWickMBesingerUGeursenRGHigh dose intravenous gammaglobulin for myasthenia gravisLancet1984183818488496200741
   PubMed Web of Science ®Google Scholar
• GajdosPOutinHDElkharratDHigh dose intravenous gammaglobulin for myasthenia gravisLancet1984183734064076198570
   PubMed Web of Science ®Google Scholar
• ArsuraELExperience with intravenous immunoglobulin in myasthenia gravisClin Immunol Immunopathol.1989532 Pt 2S1701792791345
   PubMedGoogle Scholar
• van der MercheFGvan DoornPAThe current place of high-dose immunoglobulins in the treatment of neuromuscular disordersMuscle Nerve19972021361479040650
   PubMed Web of Science ®Google Scholar
• AchironABarakYMironSSarova-PinhasIImmunoglobulin treatment in refractory myasthenia gravisMuscle Nerve200023455155510716766
   PubMed Web of Science ®Google Scholar
• HilkevichODroryVEChapmanJKorczynADThe use of intravenous immunoglobulin as maintenance therapy in myasthenia gravisClin Neuropharmacol200124317317611391130
   PubMed Web of Science ®Google Scholar
• Perez-NellarJDominquezAMLlorens-FigueroaJAA comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myastheniaRev Neurol200133541341611727205
   PubMed Web of Science ®Google Scholar
• JensenPBrilVA comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravisJ Clin Neuromuscul Dis20089335235518344718
   PubMedGoogle Scholar
• WolfeGIBarohnRJFosterBMMyasthenia Gravis-IVIG Study Group. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisMuscle Nerve200226454955212362423
   PubMed Web of Science ®Google Scholar
• ZinmanLNgEBrilVIV immunoglobulin in patients with myasthenia gravis. A randomized controlled trialNeurology2007681183784117353471
   PubMed Web of Science ®Google Scholar
• GajdosPChevretSClairBTranchantCChastangCClinical trial of plasma exchange and high dose immunoglobulin in myasthenia gravisAnn Neurol19974167897969189040
   PubMed Web of Science ®Google Scholar
• RonagerJRavnborgMHermansenIVolstrupSImmunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravisArtif Organs2001251296797311843764
   PubMed Web of Science ®Google Scholar
• GajdosPChevretSToykaKIntravenous immunoglobulin for myasthenia gravisCochrane Database Syst Rev.20081CD00227718254004
   PubMed Web of Science ®Google Scholar
• GajdosPTranchantCClairBTreatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1 g/kg versus 2 g/kg: a randomized double blind clinical trialArch Neurol200562111689169316286541
   PubMedGoogle Scholar
• SathasivamSEvidence for use of intravenous immunoglobulin and plasma exchange in generalised mysasthenia gravisAdv Clin Neurosci Rehabil200991810
   Google Scholar
• ThorlaciusSLefvertAKAarliJAPlasma exchange in myasthenia gravis: effect on anti-AChR antibodies and other autoantibodiesActa Neurol Scand19867464864903825504
   PubMed Web of Science ®Google Scholar
• YehJHChenWHChiuHCBaiCHMuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravisJ Neurol20072631–2191193
   Google Scholar
• PinchingASPetersDKRemission of myasthenia gravis following plasma exchangeLancet1976280001373137663848
   PubMed Web of Science ®Google Scholar
• BehanPOShakirRASimpsonJABurnettAKAllanTLHaaseAGPlasma exchange combined with immunosuppressive therapy in myasthenia gravisLancet19792814043844089500
   PubMed Web of Science ®Google Scholar
• DauCResponse to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patientsAnn N Y Acad Sci19813777007086951494
   PubMed Web of Science ®Google Scholar
• OlarteMRShoenfeldtRSPennASLovelaceRERowlandLPEffect of plasmapheresis in myasthenia gravisAnn N Y Acad Sci19813777257286951496
   PubMed Web of Science ®Google Scholar
• FornasariPMRivaGPiccoloGCosiVLombardiMShort and long-term clinical effects of plasma exchange in 33 cases of myasthenia gravisInt J Artif Organs1985831591624030134
   PubMed Web of Science ®Google Scholar
• HuoJTLongHLLuoXXuJZClinical study of double filtration plasmapheresis for treatment of refractory myasthenia gravisNan Fang Yi Ke DA Xue Xue Bao [Journal of Southern Medical University]2007273355357 Chinese
   PubMedGoogle Scholar
• Lazo-LangnerAEspinosa-PoblanoITirado-CardenasNTherapeutic plasma exchange in Mexico: experience from a single institutionAm J Hematol2002701162111994977
   PubMed Web of Science ®Google Scholar
• Carandina-MaffeisRNucciAMarquesJFJrPlasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patientsArq Neuropsiquiatr.2004622B39139515273832
   PubMed Web of Science ®Google Scholar
• YucesanCArslanOAratMTherapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 casesTransfus Apher Sci200736110310717224307
   PubMed Web of Science ®Google Scholar
• QureshiAIChoudhryMAAkbarMSPlasma exchange versus intravenous immunoglobulin treatment in myasthenic crisisNeurology199952362963210025801
   PubMed Web of Science ®Google Scholar
• MantegazzaRBruzzoneERegiBSingle donor plasma in therapeutic exchange for myasthenia gravisInt J Artif Organs19871053153183679573
   PubMed Web of Science ®Google Scholar
• NagayasuTYamayoshiTMatsumotoKBeneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravisJpn J Thorac Cardiovasc Surg20055312715724495
   PubMedGoogle Scholar
• YehJHChenWHHuangKMChiuHCPrethymectomy plasmapheresis in myasthenia gravisJ Clin Apher200520421722116035101
   PubMed Web of Science ®Google Scholar
• GajdosPSimonNde Rohan-ChabotPRaphaelJCGoulonMLong-term effects of plasma exchange in myasthenia. Results of a randomized studyPresse Med198312159399426221247
   PubMed Web of Science ®Google Scholar
• YehJHChiuHCPlasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily scheduleActa Neurol Scand199999314715110100957
   PubMed Web of Science ®Google Scholar
• TrikhaISinghSGoyalVShuklaGBhasinRBehariMComparative efficacy of low dose daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trialJ Neurol2007254898999517694386
   PubMed Web of Science ®Google Scholar
• GronsethGSBarohnRJPractice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200055171510891896
   PubMed Web of Science ®Google Scholar
• GoldRSchneider-GoldRCurrent and future standards in treatment of myasthenia gravisNeurotherapeutics20085453554119019304
   PubMed Web of Science ®Google Scholar
• KumarVKaminskiHJTreatment of myasthenia gravisCurr Neurol Neurosci Rep2011111899620927659
   PubMed Web of Science ®Google Scholar
• LeiteMIStrobelPJonesMFewer thymic changes in MuSK antibody positive than in MuSK antibody-negative MGAnn Neurol200557344444815732104
   PubMed Web of Science ®Google Scholar
• SouroujonMCBrennerTFuchsSDevelopment of novel therapies for MG: studies in animal modelsAutoimmunity2010435–644646020298126
   PubMed Web of Science ®Google Scholar
• LagoumintzisGZisimopoulouPKordasGLazaridisKPoulasKTzartosSJRecent approaches to the development of antigen-specific immunotherapies for myasthenia gravisAutoimmunity2010435–643644520187712
   PubMed Web of Science ®Google Scholar
• MeinlEKlinkertWEWekerleHThe thymus in myasthenia gravis Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis ratAm J Pathol1991139599510081951638
   PubMed Web of Science ®Google Scholar
• BartfeldDFuchsSSpecific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptorProc Natl Acad Sci U S A197875840064010279016
   PubMed Web of Science ®Google Scholar
• WangZYQiaoJLinkHSuppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptorJ Neuroimmunol19934422092148505410
   PubMed Web of Science ®Google Scholar
• OkumuraSMcIntoshKDrachmanDBOral administration of acetylcholine receptor: effects on experimental myasthenia gravisAnn Neurol19943657047137979216
   PubMed Web of Science ®Google Scholar
• MaCGZhangGXXiaoBGLinkJOlssonTLinkHSuppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptorJ Neuroimmunol199558151607537280
   PubMed Web of Science ®Google Scholar
• DrachmanDBOkumuraSAdamsRNMcIntoshKROral tolerance in myasthenia gravisAnn NY Acad Sci19967782582728610979
   PubMed Web of Science ®Google Scholar
• ShiFDBaiXFLiHLHuangYMVan der MeidePHLinkHNasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animalsClin Exp Immunol199811135065129528890
   PubMed Web of Science ®Google Scholar
• TzartosSJLindstromJMMonoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunitsProc Natl Acad Sci U S A19807727557596153804
   PubMed Web of Science ®Google Scholar
• ImSHBarchanDFuchsSSouroujanMCSuppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragmentJ Clin Invest1999104121723173010606626
   PubMed Web of Science ®Google Scholar
• BarchanDSouroujonMCImSHAntozziCFuchsSAntigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha- subunitProc Natl Acad Sci U S A199996148086809110393952
   PubMed Web of Science ®Google Scholar
• ImSHBarchanDFuchsSSouroujonMCMechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravisJ Neuroimmunol20001111–216116811063834
   PubMed Web of Science ®Google Scholar
• MaitiPKFefermanTImSHSouroujonMCFuchsSImmunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragmentJ Neuroimmunol20041521–211212015223243
   PubMed Web of Science ®Google Scholar
• WuBDengCGoluszkoEChristadossPTolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravisJ Immunol19971596301630239300727
   PubMed Web of Science ®Google Scholar
• KarachunskiPIOstlieNSOkitaDKGarmanRConti-FineBMSubcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravisJ Neuroimmunol1999931–210812110378874
   PubMed Web of Science ®Google Scholar
• ShenoyMOshimaMAtassiMZChristadossPSuppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146–162 of acetylcholine receptorClin Immunol Immunopathol19936632302387679342
   PubMedGoogle Scholar
• BaggiFAndreettaFCaspaniEOral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravisJ Clin Invest199910491287129510545527
   PubMed Web of Science ®Google Scholar
• SouroujonMCMaitiPKFefermanTImSHRavehLFuchsSSuppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factorsAnn NY Acad Sci200399853353614592924
   PubMed Web of Science ®Google Scholar
• ShengJRLiLCGaneshBBPrabhakarBSMeriggioliMNRegulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravisClin Immunol2008128217218018502693
   PubMed Web of Science ®Google Scholar
• YarilinDDuanRHuangYMXiaoBGDendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravisClin Exp Immunol2002127221421911876742
   PubMed Web of Science ®Google Scholar
• ImSHBarchanDMaitiPKRavehLSouroujonMCFuchsSSuppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18FASEB J200115122140214811641240
   PubMed Web of Science ®Google Scholar
• ImSHBarchanDMaitiPKFuchsSSouroujonMCBlockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4J Immunol2001166116893689811359850
   PubMed Web of Science ®Google Scholar
• SoltysJKusnerLLYoungANovel complement inhibitor limits severity of experimentally myasthenia gravisAnn Neurol2009651677519194881
   PubMed Web of Science ®Google Scholar
• YamazakiZFujimoriYTakahamaTEfficiency and biocompatibility of a new immunosorbentTrans Am Soc Artif Intern Organs1982283183237164255
   PubMedGoogle Scholar
• MaticGWinklerRETiessMRamlowWSelective apheresis-time for a changeInt J Artif Organs20012414711266041
   PubMed Web of Science ®Google Scholar
• PtakJChanges of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravisTransfus Apher Sci200430212512915062750
   PubMed Web of Science ®Google Scholar
• TakamoriMMarutaTImmunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptorTher Apher20015534035011778918
   PubMedGoogle Scholar
• GuoCYLiZYXuMQYuanJMPreparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serumJ Immunol Methods20053031–214214716040047
   PubMed Web of Science ®Google Scholar
• ZisimopoulouPLagoumintzisGPoulasKTzartosSAntigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients’ sera using Escherichia coli-expressed receptor domainsJ Neuroimmunol20082001–213314118603305
   PubMed Web of Science ®Google Scholar